Long‐term outcomes of cribriform‐positive and cribriform‐negative prostate cancer treated with radical prostatectomy in the <scp>ProtecT</scp> trial

In the ProtecT trial, the 15-year risk of metastasis or death after RP was a binary outcome defined by cribriform status. The concentration of risk in men with cribriform-positive, high-grade and/or pT3b tumours identifies a target population for adjuvant therapy trials, while supporting management de-escalation for most RP patients.